"PLA has an industry leading sensitivity of multiplexed immunoassays while only consuming minute amounts of sample. Researchers can now access precious and limited biobanked serological materials and with our service find new protein biomarker signatures," says Dr Simon Fredriksson, Chief Scientific Officer at Olink Bioscience.

The PLA immunoassay technology employs two primary antibodies linked to DNA strands, which upon simultaneous and proximal binding to the target protein, will be ligated. Once ligated, they form a PCR amplicon typically detected with real-time quantatitive PCR. The assay is performed as a convenient homogenous assay without any washing steps and is characterized by low sample consumption, high sensitivity, and multiplexing capability as recently published by Lundberg et al 2011, Jan 17, Mol Cell Proteomics, PMID: 21242282.